Agios Pharmaceuticals (NASDAQ:AGIO) has been given a $125.00 price objective by equities research analysts at Piper Jaffray Companies in a research report issued to clients and investors on Thursday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Piper Jaffray Companies’ price objective points to a potential upside of 50.33% from the stock’s current price.
A number of other research analysts have also recently commented on AGIO. BidaskClub cut Agios Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, June 18th. SunTrust Banks reiterated a “buy” rating and issued a $123.00 price target on shares of Agios Pharmaceuticals in a research note on Monday, July 23rd. Cann reaffirmed a “hold” rating on shares of Agios Pharmaceuticals in a research report on Friday, July 20th. Credit Suisse Group set a $95.00 target price on Agios Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, May 7th. Finally, ValuEngine raised Agios Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, May 2nd. Four equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $96.27.
Hot Bank Stocks To Invest In 2019: Cellectis S.A.(CLLS)
Advisors' Opinion:- [By Stephan Byrd]
Shares of Cellectis SA (NASDAQ:CLLS) have earned an average recommendation of “Hold” from the nine research firms that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $42.00.
Hot Bank Stocks To Invest In 2019: Attunity Ltd.(ATTU)
Advisors' Opinion:- [By Joseph Griffin]
Attunity Ltd (NASDAQ:ATTU) has earned an average recommendation of “Buy” from the six ratings firms that are currently covering the firm, Marketbeat reports. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $12.33.
- [By Joseph Griffin]
Get a free copy of the Zacks research report on Attunity (ATTU)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Logan Wallace]
Get a free copy of the Zacks research report on Attunity (ATTU)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Hot Bank Stocks To Invest In 2019: ASML Holding N.V.(ASML)
Advisors' Opinion:- [By Ethan Ryder]
ASML (NASDAQ: ASML) and ACM Research (NASDAQ:ACMR) are both computer and technology companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.
- [By Max Byerly]
Get a free copy of the Zacks research report on ASML (ASML)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Jon C. Ogg]
ASML Holding N.V. (NASDAQ: ASML) was down 2.6% to $197.02 on Friday morning. The stock has a 52-week trading range of $126.03 to $216.00 and a consensus analyst target price of $196.81.
- [By Max Byerly]
Front Row Advisors LLC increased its holdings in ASML Holding NV (NASDAQ:ASML) by 15.5% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,247 shares of the semiconductor company’s stock after purchasing an additional 703 shares during the period. Front Row Advisors LLC’s holdings in ASML were worth $1,042,000 as of its most recent SEC filing.
No comments:
Post a Comment